UY32409A - Compuesto de anillo fusionado y su uso - Google Patents

Compuesto de anillo fusionado y su uso

Info

Publication number
UY32409A
UY32409A UY0001032409A UY32409A UY32409A UY 32409 A UY32409 A UY 32409A UY 0001032409 A UY0001032409 A UY 0001032409A UY 32409 A UY32409 A UY 32409A UY 32409 A UY32409 A UY 32409A
Authority
UY
Uruguay
Prior art keywords
fusioned
ring compound
receptor
diseases
peroxisomes
Prior art date
Application number
UY0001032409A
Other languages
English (en)
Inventor
Igawa Hideyuki
Maekawa Tsuyoshi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY32409A publication Critical patent/UY32409A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Se provee un nuevo compuesto representado por la siguiente formula , en donde cada signo es como se definió en le memoria descriptiva o una de sus sales, que tiene una actividad antagonista del receptor de angiotensina II y una actividad agonista del receptor y activado por el proliferador de peroxisomas y es de utilidad como un agente para la prevención o el tratamiento de enfermedades circulatorias tales como hipertensión, y similares y/o enfermedades metabólicas tales como diabetes, y similares, y otros
UY0001032409A 2009-01-30 2010-01-29 Compuesto de anillo fusionado y su uso UY32409A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009020720 2009-01-30

Publications (1)

Publication Number Publication Date
UY32409A true UY32409A (es) 2010-08-31

Family

ID=42026435

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032409A UY32409A (es) 2009-01-30 2010-01-29 Compuesto de anillo fusionado y su uso

Country Status (37)

Country Link
US (4) US8592431B2 (es)
EP (1) EP2384327B1 (es)
JP (2) JP4892649B1 (es)
KR (1) KR20110113758A (es)
CN (2) CN103788097B (es)
AR (1) AR075344A1 (es)
AU (1) AU2010208863A1 (es)
CA (1) CA2750710C (es)
CL (1) CL2011001848A1 (es)
CO (1) CO6362011A2 (es)
CR (1) CR20110463A (es)
CY (1) CY1114530T1 (es)
DK (1) DK2384327T3 (es)
DO (1) DOP2011000249A (es)
EA (1) EA019823B1 (es)
EC (1) ECSP11011294A (es)
ES (1) ES2433225T3 (es)
GE (1) GEP20135961B (es)
HK (1) HK1162505A1 (es)
HR (1) HRP20131017T1 (es)
IL (1) IL214283A0 (es)
MA (1) MA33071B1 (es)
ME (1) ME01621B (es)
MX (1) MX2011008058A (es)
MY (1) MY152946A (es)
NZ (1) NZ594606A (es)
PE (1) PE20120593A1 (es)
PL (1) PL2384327T3 (es)
PT (1) PT2384327E (es)
RS (1) RS53012B (es)
SG (1) SG173135A1 (es)
SI (1) SI2384327T1 (es)
TN (1) TN2011000368A1 (es)
TW (2) TWI468410B (es)
UY (1) UY32409A (es)
WO (1) WO2010087515A1 (es)
ZA (1) ZA201105867B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011008058A (es) 2009-01-30 2011-09-01 Takeda Pharmaceutical Compuesto de anillo fusionado y su uso.
SI2655375T1 (sl) 2010-12-23 2015-03-31 Sanofi Derivati pirimidinona, njihova priprava in njihova farmacevtska uporaba
CZ304252B6 (cs) * 2011-04-11 2014-01-29 Zentiva, K. S. Způsob výroby 2-ethoxy-1-((2´-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)bifenyl-4-yl)methyl)-1H-benzo[d]imidazol-7-karboxylátů a jejich převedení na azilsartan
US11091489B2 (en) 2016-06-20 2021-08-17 Novartis Ag Crystalline forms of a triazolopyrimidine compound
SG11202002632VA (en) 2017-09-26 2020-04-29 Ecolab Usa Inc Acidic/anionic antimicrobial and virucidal compositions and uses thereof
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CN116348458A (zh) 2019-08-14 2023-06-27 因赛特公司 作为cdk2抑制剂的咪唑基嘧啶基胺化合物
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN112745319B (zh) * 2019-10-30 2022-06-17 中国科学院上海药物研究所 一类取代三环结构的化合物、其制备方法及用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472967A (en) 1991-02-20 1995-12-05 Synthelabo 4-pyrimidinone derivatives their preparation and their application in therapy
FR2672892B1 (fr) 1991-02-20 1994-01-14 Synthelabo Derives de 4-pyrimidinones, leur preparation et leur application en therapeutique.
TW251288B (es) * 1991-06-27 1995-07-11 Takeda Dharm Industry Co Ltd
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
IT1250749B (it) * 1991-08-02 1995-04-21 Luso Farmaco Inst Composti eterociclici ad attivita' a ii antagonista
US5387747A (en) * 1992-02-24 1995-02-07 Laboratoires Upsa Triazolopyrimidine derivatives which are angiotensin II receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present
FR2687677B1 (fr) * 1992-02-24 1996-10-11 Union Pharma Scient Appl Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant.
US5389632A (en) * 1992-02-24 1995-02-14 Laboratoires Upsa Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists
IT1263804B (it) 1993-01-22 1996-09-03 Luso Farmaco Inst Derivati pirimidinonici fusi con eterocicli azotati ad attivita' a ii antagonista
GB9406573D0 (en) 1994-03-31 1994-05-25 Merck Sharp & Dohme Medicaments
RO118046B1 (ro) 1995-06-07 2003-01-30 Gd Searle & Co Chicago Asociere farmaceutica
EP0831911B1 (en) 1995-06-07 2002-04-17 G.D. Searle & Co. Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure
WO1996040255A2 (en) 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
WO1996040256A1 (en) 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination of an angiotensin ii antagonist and spironolactone
FR2812876B1 (fr) 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
SE0101579D0 (sv) 2001-05-04 2001-05-04 Astrazeneca Ab New compounds
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
TW200418835A (en) 2003-01-24 2004-10-01 Tanabe Seiyaku Co A pyrazolopyrimidine compound and a process for preparing the same
WO2005020984A2 (en) 2003-08-29 2005-03-10 Aaipharma Inc. Method of reducing the risk of oxidative stress
CA2553724A1 (en) * 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
AU2005250285B2 (en) 2004-06-02 2011-08-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
JP2008503546A (ja) 2004-06-23 2008-02-07 ゾルファイ　ファーマスーティカルズ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング Ｎｅｐ阻害剤、内因性エンドセリン産生系阻害剤およびａｔ１受容体アンタゴニスト阻害剤を含有する医薬組成物
US20050288272A1 (en) * 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
JP5140587B2 (ja) 2005-07-27 2013-02-06 モル リサーチ アプリケーションズ リミテッド 腎臓、血管および軟骨の病理を治療におけるレニン−アンギオテンシン系の阻害
WO2007053406A1 (en) 2005-10-28 2007-05-10 Novartis Ag Combinations of antihypertensive and cholesterol lowering agents
WO2007051007A2 (en) 2005-10-28 2007-05-03 Novartis Ag Combination of antihypertensives with cholesterol-lowering agent
US20080064871A1 (en) 2006-05-26 2008-03-13 Japan Tobacco Inc. Production Method of Nitrogen-Containing Fused Ring Compounds
CA2668725A1 (en) 2006-11-09 2008-05-22 Ore Pharmaceuticals Inc. Breast cancer screening and treatment methods
US20090012052A1 (en) * 2006-11-09 2009-01-08 Ore Pharmaceuticals Inc. Method for treating er+ breast cancer
MX2009005449A (es) * 2006-11-24 2009-06-02 Takeda Pharmaceutical Compuesto heteromonociclico y uso del mismo.
WO2008143262A1 (ja) * 2007-05-21 2008-11-27 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
WO2009039069A1 (en) 2007-09-20 2009-03-26 University Of Rochester Method and compositions for treatment or prevention of inflammatory conditions
MX2010010525A (es) 2008-03-24 2010-10-25 Novartis Ag Inhibidores de metaloproteasa de matriz basados en aril-sulfonamida.
CA2723372A1 (en) 2008-05-05 2009-11-12 University Of Rochester Methods and compositions for the treatment or prevention of pathological cardiac remodeling and heart failure
MX2011008058A (es) 2009-01-30 2011-09-01 Takeda Pharmaceutical Compuesto de anillo fusionado y su uso.

Also Published As

Publication number Publication date
DK2384327T3 (da) 2013-10-28
SG173135A1 (en) 2011-08-29
EP2384327A1 (en) 2011-11-09
CR20110463A (es) 2011-12-01
JP2012513952A (ja) 2012-06-21
HK1162505A1 (en) 2012-08-31
CO6362011A2 (es) 2012-01-20
PL2384327T3 (pl) 2013-12-31
EP2384327B1 (en) 2013-07-31
IL214283A0 (en) 2011-09-27
DOP2011000249A (es) 2011-09-15
EA201101138A1 (ru) 2012-04-30
CY1114530T1 (el) 2017-01-25
KR20110113758A (ko) 2011-10-18
TW201031669A (en) 2010-09-01
ECSP11011294A (es) 2011-09-30
MY152946A (en) 2014-12-15
CA2750710C (en) 2018-09-04
JP4892649B1 (ja) 2012-03-07
HRP20131017T1 (hr) 2013-12-06
US20140046056A1 (en) 2014-02-13
ES2433225T3 (es) 2013-12-10
CN102369205A (zh) 2012-03-07
PE20120593A1 (es) 2012-05-21
US8592431B2 (en) 2013-11-26
TN2011000368A1 (en) 2013-03-27
US20110294832A1 (en) 2011-12-01
MX2011008058A (es) 2011-09-01
CA2750710A1 (en) 2010-08-05
PT2384327E (pt) 2013-11-07
AU2010208863A1 (en) 2011-09-08
WO2010087515A1 (en) 2010-08-05
US8921379B2 (en) 2014-12-30
ZA201105867B (en) 2012-10-31
CN102369205B (zh) 2014-10-29
US20100197683A1 (en) 2010-08-05
CL2011001848A1 (es) 2012-02-03
ME01621B (me) 2014-09-20
TW201444848A (zh) 2014-12-01
NZ594606A (en) 2013-06-28
US9115136B2 (en) 2015-08-25
CN103788097B (zh) 2016-03-30
JP2011251970A (ja) 2011-12-15
GEP20135961B (en) 2013-11-11
JP5676379B2 (ja) 2015-02-25
US20110288087A1 (en) 2011-11-24
CN103788097A (zh) 2014-05-14
EA019823B1 (ru) 2014-06-30
MA33071B1 (fr) 2012-02-01
RS53012B (en) 2014-04-30
TWI468410B (zh) 2015-01-11
AR075344A1 (es) 2011-03-23
US8283353B2 (en) 2012-10-09
SI2384327T1 (sl) 2013-12-31

Similar Documents

Publication Publication Date Title
UY32409A (es) Compuesto de anillo fusionado y su uso
PE20150200A1 (es) Formulacion de anticuerpos
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
CL2014001280A1 (es) Compuestos derivados de 4-fenil -piridinas sustituidas, moduladores del receptor de nk1; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de la emesis, disfuncion vesical, depresion o ansiedad
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2012003053A1 (es) Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad.
UY31863A (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
CL2008003690A1 (es) Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos.
CL2014000032A1 (es) Compuestos derivados de bencilamina, inhibidores de calicreina plasmatica; composicion farmaceutica; y su uso para el tratamiento de agudeza visual deteriorada, retinopatia diabetica, edema macular diabetico, hipotension cardiomiopatia, cancer, entre otros
DOP2012000263A (es) Compuestos quimicos
UY33379A (es) Compuestos de morfolina
CO6541645A2 (es) Compuestos de indol y su uso farmaceutico
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
UY34832A (es) TIAZOLES SUSTITUIDOS POR CARBOXAMIDA O SULFONAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUÉRFANO RORy (lambda)
CL2013002053A1 (es) Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct
CL2012001911A1 (es) Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa.
CL2013000380A1 (es) Compuestos heterociclicos derivados de [1,2,4] tiadiazina, moduladores positivos del receptor de ampa; medicamento que los contiene; y su uso para la prevencion o el tratamiento de depresion, enfermedad de alzheimer, esquizofrenia o trastorno de hiperactividad de deficit de atencion.
CL2012003681A1 (es) Compuestos derivados de piperidina; composicion farmaceutica; y su uso como inhibidores de acetil-coa carboxilasa para el tratamiento de trastornos metabolicos, tales como obesidad y diabetes.
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
DOP2012000006A (es) Agonista de gpr119
CR20110100A (es) Nuevos derivados de sulfamida sustituida
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
CL2009000004A1 (es) Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia.
GT201400050A (es) Derivados de anilina, su preparación y su aplicación terapéutica

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181211